News

Are we using biologic therapy properly?

The introduction of infliximab (Remicade), the first biologic therapy approved for the treatment of inflammatory bowel diseases (IBD), did not result in lower rates of hospitalizations or intestinal surgeries among patients living with IBD in Ontario, according to a study published by authors from several Canadian hospitals and ICES in the journal Gut. The authors studied trends in hospitalizations, surgeries and ...

Read More »

Cigarette smoke makes MRSA superbug bacterium more drug-resistant

Cigarette smoke can make MRSA bacterial strains more resistant to antibiotics, new research from the University of Bath has shown. In addition cigarette smoke exposure can make some strains of Staphylococcus aureus, a microbe present in 30 to 60 percent of the global population and responsible for many diseases, some fatal, more invasive and persistent, although the effect is not universal ...

Read More »

New material could make it easier to remove colon polyps

More than 15 million colonoscopies are performed in the United States every year, and in at least 20 percent of those, gastroenterologists end up removing precancerous growths from the colon. Eliminating these early-stage lesions, known as polyps, is the best way to prevent colon cancer from developing. To reduce the risk of tearing the colon during this procedure, doctors often ...

Read More »

John Whelan Joins Healthmark Industries

John Whelan

Healthmark Industries is proud to announce John Whelan as the newest Clinical Education Coordinator. “We are very pleased to welcome John to Healthmark Industries,” says Vice President Ralph Basile. “His expert knowledge and experience in the institutional sterilization and high level disinfection field will play a vital role in providing guidance and support to our customers.” Whelan comes to Healthmark ...

Read More »